$0.62
0.84% day before yesterday
NYSE, Dec 27, 10:00 pm CET
ISIN
US9286611077
Symbol
VNRX
Sector

VolitionRX Stock price

$0.62
-0.08 11.74% 1M
-0.02 2.54% 6M
-0.10 14.23% YTD
-0.09 13.18% 1Y
-2.64 81.08% 3Y
-3.99 86.63% 5Y
-3.29 84.23% 10Y
NYSE, Closing price Fri, Dec 27 2024
-0.01 0.84%
ISIN
US9286611077
Symbol
VNRX
Sector

Key metrics

Market capitalization $59.02m
Enterprise Value $58.36m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 45.24
P/S ratio (TTM) P/S ratio 45.75
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 97.50%
Revenue (TTM) Revenue $1.29m
EBIT (operating result TTM) EBIT $-29.98m
Free Cash Flow (TTM) Free Cash Flow $-14.48m
Cash position $5.41m
EPS (TTM) EPS $-0.36
P/E forward negative
P/S forward 40.51
EV/Sales forward 40.05
Short interest 0.61%
Show more

Is VolitionRX a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

VolitionRX Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a VolitionRX forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a VolitionRX forecast:

Buy
67%
Hold
33%

Financial data from VolitionRX

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1.29 1.29
98% 98%
100%
- Direct Costs 1.34 1.34
1% 1%
104%
-0.06 -0.06
92% 92%
-5%
- Selling and Administrative Expenses 13 13
13% 13%
1,039%
- Research and Development Expense 15 15
15% 15%
1,177%
-29 -29
16% 16%
-2,220%
- Depreciation and Amortization 1.34 1.34
1% 1%
104%
EBIT (Operating Income) EBIT -30 -30
15% 15%
-2,324%
Net Profit -30 -30
12% 12%
-2,316%

In millions USD.

Don't miss a Thing! We will send you all news about VolitionRX directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

VolitionRX Stock News

Neutral
PRNewsWire
17 days ago
Volition to participate in the upcoming 14th Annual LifeSci Partners Corporate Access Event on January 15 th, 2025 at the Beacon Grand Hotel in San Francisco. HENDERSON, Nev.
Neutral
PRNewsWire
19 days ago
HENDERSON, Nev. , Dec. 10, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which shows that its Nu.Q® Cancer Test differentiated between malignant and benign pulmonary nodules, found by Low Dose CT (LDCT) scan, in patients suspected of lung cancer.
Neutral
PRNewsWire
23 days ago
Up to $1.9 million up front with up to an additional $2.7 million of potential aggregate gross proceeds upon the exercise in full of common stock purchase warrants HENDERSON, Nev , Dec. 6, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced today that it has entered into definitive agreements for the purcha...
More VolitionRX News

Company Profile

VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.

Head office United States
CEO Cameron Reynolds
Employees 110
Founded 1998
Website www.volition.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today